Product Description
Degarelix injection is used to treat advanced prostate cancer (cancer that begins in the prostate [a male reproductive gland]). Degarelix injection is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. This may slow or stop the spread of prostate cancer cells that need testosterone to grow. (Sourced from: https://medlineplus.gov/druginfo/meds/a609022.html)
Mechanisms of Action: GnRH Antagonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Ferring
Company Location: Europe
Company Founding Year: 1950
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Canada, France, United States
Active Clinical Trial Count: 14
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Adenocarcinoma|Prostate Cancer
Phase 2: Male Breast Cancer
Phase 1: Bladder Cancer|Transitional Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05050084 |
GUIDANCE | P3 |
Recruiting |
Adenocarcinoma|Prostate Cancer |
2026-11-11 |
2025-03-18 |
Primary Endpoints |
|
2023-507672-52-00 |
CAAA802A12101 | P2 |
Recruiting |
Prostate Cancer |
2026-08-01 |
2025-05-02 |
Treatments |
|
NCT05501704 |
ETHAN | P2 |
Recruiting |
Male Breast Cancer |
2026-04-01 |
12% |
2025-02-07 |
Primary Endpoints|Treatments |
NCT05839119 |
TASUC-Neo | P1 |
Recruiting |
Bladder Cancer|Transitional Cell Carcinoma |
2027-01-01 |
2025-03-22 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT05189457 |
MCC-21139 | P2 |
Active, not recruiting |
Prostate Cancer |
2027-07-15 |
12% |
2024-07-24 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06066437 |
The Nautilus Trial | P2 |
Active, not recruiting |
Prostate Cancer |
2026-12-31 |
14% |
2026-03-07 |
Primary Endpoints |
NCT03069937 |
Pro00061532 | P2 |
Active, not recruiting |
Adenocarcinoma|Prostate Cancer |
2024-09-30 |
41% |
2024-09-20 |
|
2016-002854-19 |
2016-002854-19 | P2 |
Completed |
Prostate Cancer |
2024-07-22 |
2025-06-29 |
Treatments |
|
NCT04513717 |
PREDICT-RT* | P3 |
Active, not recruiting |
Prostate Cancer|Adenocarcinoma |
2033-12-31 |
2025-09-12 |
Primary Endpoints |
|
2022-502373-42-00 |
S65935 | P3 |
Recruiting |
Prostate Cancer |
2032-06-01 |
2025-05-02 |
Treatments |
|
NCT03009981 |
AFT-19 | P3 |
Completed |
Prostate Cancer |
2025-06-25 |
25% |
2025-11-25 |
|
NCT04301414 |
Neo-Red-P | P1 |
Completed |
Prostate Cancer |
2025-03-13 |
4% |
2025-08-08 |
|
NCT07455903 |
LHRPC | P2 |
Not yet recruiting |
Prostate Cancer |
2029-10-01 |
12% |
2026-03-07 |
|
NCT04176081 |
SChLAP/IDC | P2 |
Not yet recruiting |
Prostate Cancer |
2028-12-01 |
63% |
2024-01-25 |
Primary Endpoints|Start Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/31/2023 |
News Article |
Insights into Degarelix Market 2023 Reach and Revenue Projections for 2029 |
|
01/13/2022 |
News Article |
Global Anticancer Peptide Drug Market Clinical Research Trials Outlook 2026 |
|
03/17/2021 |
News Article |
Worldwide Peptide Cancer Therapeutics Industry to 2026 - Featuring Novartis, Amgen and Pfizer Among Others |
|
03/16/2021 |
News Article |
Global Peptide Cancer Therapeutics Market (2021 to 2026) - Drug Dosage, Price & Clinical Trials Insight |